Parkman Healthcare Partners LLC Has $11.33 Million Stock Position in Waters Corporation $WAT

Parkman Healthcare Partners LLC grew its stake in Waters Corporation (NYSE:WAT) by 14.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 30,206 shares of the medical instruments supplier’s stock after purchasing an additional 3,759 shares during the period. Parkman Healthcare Partners LLC’s holdings in Waters were worth $11,328,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. BlackRock Inc. bought a new position in shares of Waters during the 2nd quarter worth approximately $3,182,191,000. Norges Bank acquired a new stake in Waters in the 4th quarter valued at $265,751,000. Veritas Asset Management LLP grew its position in Waters by 112.3% in the fourth quarter. Veritas Asset Management LLP now owns 1,241,206 shares of the medical instruments supplier’s stock valued at $471,447,000 after acquiring an additional 656,436 shares during the period. Price T Rowe Associates Inc. MD grew its position in Waters by 509.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 671,103 shares of the medical instruments supplier’s stock valued at $254,906,000 after acquiring an additional 561,047 shares during the period. Finally, Marshall Wace LLP raised its stake in Waters by 1,611.3% during the fourth quarter. Marshall Wace LLP now owns 581,063 shares of the medical instruments supplier’s stock worth $220,705,000 after acquiring an additional 547,109 shares in the last quarter. 94.01% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Christopher A. Kuebler sold 3,626 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $397.94, for a total transaction of $1,442,930.44. Following the transaction, the director owned 17,808 shares in the company, valued at $7,086,515.52. This represents a 16.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.31% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Piper Sandler started coverage on shares of Waters in a research note on Thursday, June 11th. They issued a “neutral” rating and a $400.00 target price on the stock. Stifel Nicolaus set a $420.00 target price on shares of Waters in a research report on Wednesday, August 5th. The Goldman Sachs Group lifted their price target on shares of Waters from $380.00 to $425.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Guggenheim restated a “buy” rating and issued a $440.00 price target on shares of Waters in a research report on Wednesday, July 8th. Finally, Morgan Stanley set a $430.00 price objective on shares of Waters in a research note on Wednesday, August 5th. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, Waters currently has an average rating of “Moderate Buy” and a consensus price target of $420.35.

Waters Trading Up 0.0%

Shares of WAT opened at $410.79 on Tuesday. The stock has a fifty day moving average price of $382.85 and a two-hundred day moving average price of $347.24. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.29 and a current ratio of 1.86. Waters Corporation has a 52-week low of $282.77 and a 52-week high of $421.74. The company has a market cap of $40.36 billion, a price-to-earnings ratio of 102.44, a PEG ratio of 2.39 and a beta of 1.19.

Waters (NYSE:WAT) last posted its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $3.05 EPS for the quarter, topping analysts’ consensus estimates of $3.01 by $0.04. The company had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.62 billion. Waters had a return on equity of 11.27% and a net margin of 3.58%.The business’s revenue was up 113.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.95 earnings per share. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. Analysts predict that Waters Corporation will post 14.57 EPS for the current fiscal year.

Waters Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.